Cargando…

Retrospective Clinical Evaluation of a Decision-Support Software for Adaptive Radiotherapy of Head and Neck Cancer Patients

PURPOSE: This study aimed to evaluate the clinical need for an automated decision-support software platform for adaptive radiation therapy (ART) of head and neck cancer (HNC) patients. METHODS: We tested RTapp (SegAna), a new ART software platform for deciding when a treatment replan is needed, to i...

Descripción completa

Detalles Bibliográficos
Autores principales: Gros, Sebastien A. A., Santhanam, Anand P., Block, Alec M., Emami, Bahman, Lee, Brian H., Joyce, Cara
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9279735/
https://www.ncbi.nlm.nih.gov/pubmed/35847951
http://dx.doi.org/10.3389/fonc.2022.777793
_version_ 1784746465766146048
author Gros, Sebastien A. A.
Santhanam, Anand P.
Block, Alec M.
Emami, Bahman
Lee, Brian H.
Joyce, Cara
author_facet Gros, Sebastien A. A.
Santhanam, Anand P.
Block, Alec M.
Emami, Bahman
Lee, Brian H.
Joyce, Cara
author_sort Gros, Sebastien A. A.
collection PubMed
description PURPOSE: This study aimed to evaluate the clinical need for an automated decision-support software platform for adaptive radiation therapy (ART) of head and neck cancer (HNC) patients. METHODS: We tested RTapp (SegAna), a new ART software platform for deciding when a treatment replan is needed, to investigate a set of 27 HNC patients’ data retrospectively. For each fraction, the software estimated key components of ART such as daily dose distribution and cumulative doses received by targets and organs at risk (OARs) from daily 3D imaging in real-time. RTapp also included a prediction algorithm that analyzed dosimetric parameter (DP) trends against user-specified thresholds to proactively trigger adaptive re-planning up to four fractions ahead. The DPs evaluated for ART were based on treatment planning dose constraints. Warning (V(95)<95%) and adaptation (V(95)<93%) thresholds were set for PTVs, while OAR adaptation dosimetric endpoints of +10% (DE(10)) were set for all D(max) and D(mean) DPs. Any threshold violation at end of treatment (EOT) triggered a review of the DP trends to determine the threshold-crossing fraction Fx when the violations occurred. The prediction model accuracy was determined as the difference between calculated and predicted DP values with 95% confidence intervals (CI(95)). RESULTS: RTapp was able to address the needs of treatment adaptation. Specifically, we identified 18/27 studies (67%) for violating PTV coverage or parotid D(mean) at EOT. Twelve PTVs had V(95)<95% (mean coverage decrease of −6.8 ± 2.9%) including six flagged for adaptation at median Fx = 6 (range, 1–16). Seventeen parotids were flagged for exceeding D(mean) dose constraints with a median increase of +2.60 Gy (range, 0.99–6.31 Gy) at EOT, including nine with DP>DE(10). The differences between predicted and calculated PTV V(95) and parotid D(mean) was up to 7.6% (mean ± CI(95), −2.7 ± 4.1%) and 5 Gy (mean ± CI(95), 0.3 ± 1.6 Gy), respectively. The most accurate predictions were obtained closest to the threshold-crossing fraction. For parotids, the results showed that Fx ranged between fractions 1 and 23, with a lack of specific trend demonstrating that the need for treatment adaptation may be verified for every fraction. CONCLUSION: Integrated in an ART clinical workflow, RTapp aids in predicting whether specific treatment would require adaptation up to four fractions ahead of time.
format Online
Article
Text
id pubmed-9279735
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-92797352022-07-15 Retrospective Clinical Evaluation of a Decision-Support Software for Adaptive Radiotherapy of Head and Neck Cancer Patients Gros, Sebastien A. A. Santhanam, Anand P. Block, Alec M. Emami, Bahman Lee, Brian H. Joyce, Cara Front Oncol Oncology PURPOSE: This study aimed to evaluate the clinical need for an automated decision-support software platform for adaptive radiation therapy (ART) of head and neck cancer (HNC) patients. METHODS: We tested RTapp (SegAna), a new ART software platform for deciding when a treatment replan is needed, to investigate a set of 27 HNC patients’ data retrospectively. For each fraction, the software estimated key components of ART such as daily dose distribution and cumulative doses received by targets and organs at risk (OARs) from daily 3D imaging in real-time. RTapp also included a prediction algorithm that analyzed dosimetric parameter (DP) trends against user-specified thresholds to proactively trigger adaptive re-planning up to four fractions ahead. The DPs evaluated for ART were based on treatment planning dose constraints. Warning (V(95)<95%) and adaptation (V(95)<93%) thresholds were set for PTVs, while OAR adaptation dosimetric endpoints of +10% (DE(10)) were set for all D(max) and D(mean) DPs. Any threshold violation at end of treatment (EOT) triggered a review of the DP trends to determine the threshold-crossing fraction Fx when the violations occurred. The prediction model accuracy was determined as the difference between calculated and predicted DP values with 95% confidence intervals (CI(95)). RESULTS: RTapp was able to address the needs of treatment adaptation. Specifically, we identified 18/27 studies (67%) for violating PTV coverage or parotid D(mean) at EOT. Twelve PTVs had V(95)<95% (mean coverage decrease of −6.8 ± 2.9%) including six flagged for adaptation at median Fx = 6 (range, 1–16). Seventeen parotids were flagged for exceeding D(mean) dose constraints with a median increase of +2.60 Gy (range, 0.99–6.31 Gy) at EOT, including nine with DP>DE(10). The differences between predicted and calculated PTV V(95) and parotid D(mean) was up to 7.6% (mean ± CI(95), −2.7 ± 4.1%) and 5 Gy (mean ± CI(95), 0.3 ± 1.6 Gy), respectively. The most accurate predictions were obtained closest to the threshold-crossing fraction. For parotids, the results showed that Fx ranged between fractions 1 and 23, with a lack of specific trend demonstrating that the need for treatment adaptation may be verified for every fraction. CONCLUSION: Integrated in an ART clinical workflow, RTapp aids in predicting whether specific treatment would require adaptation up to four fractions ahead of time. Frontiers Media S.A. 2022-06-30 /pmc/articles/PMC9279735/ /pubmed/35847951 http://dx.doi.org/10.3389/fonc.2022.777793 Text en Copyright © 2022 Gros, Santhanam, Block, Emami, Lee and Joyce https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Oncology
Gros, Sebastien A. A.
Santhanam, Anand P.
Block, Alec M.
Emami, Bahman
Lee, Brian H.
Joyce, Cara
Retrospective Clinical Evaluation of a Decision-Support Software for Adaptive Radiotherapy of Head and Neck Cancer Patients
title Retrospective Clinical Evaluation of a Decision-Support Software for Adaptive Radiotherapy of Head and Neck Cancer Patients
title_full Retrospective Clinical Evaluation of a Decision-Support Software for Adaptive Radiotherapy of Head and Neck Cancer Patients
title_fullStr Retrospective Clinical Evaluation of a Decision-Support Software for Adaptive Radiotherapy of Head and Neck Cancer Patients
title_full_unstemmed Retrospective Clinical Evaluation of a Decision-Support Software for Adaptive Radiotherapy of Head and Neck Cancer Patients
title_short Retrospective Clinical Evaluation of a Decision-Support Software for Adaptive Radiotherapy of Head and Neck Cancer Patients
title_sort retrospective clinical evaluation of a decision-support software for adaptive radiotherapy of head and neck cancer patients
topic Oncology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9279735/
https://www.ncbi.nlm.nih.gov/pubmed/35847951
http://dx.doi.org/10.3389/fonc.2022.777793
work_keys_str_mv AT grossebastienaa retrospectiveclinicalevaluationofadecisionsupportsoftwareforadaptiveradiotherapyofheadandneckcancerpatients
AT santhanamanandp retrospectiveclinicalevaluationofadecisionsupportsoftwareforadaptiveradiotherapyofheadandneckcancerpatients
AT blockalecm retrospectiveclinicalevaluationofadecisionsupportsoftwareforadaptiveradiotherapyofheadandneckcancerpatients
AT emamibahman retrospectiveclinicalevaluationofadecisionsupportsoftwareforadaptiveradiotherapyofheadandneckcancerpatients
AT leebrianh retrospectiveclinicalevaluationofadecisionsupportsoftwareforadaptiveradiotherapyofheadandneckcancerpatients
AT joycecara retrospectiveclinicalevaluationofadecisionsupportsoftwareforadaptiveradiotherapyofheadandneckcancerpatients